Press releases
7 July 2020, Zwingenberg

Change in the Management Board of BRAIN AG

Chief Business Officer Ludger Roedder is leaving the executive board with immediate effect

The biotechnology company B.R.A.I.N. Biotechnology Research and Information Network AG announces that Chief Business Officer Ludger Roedder will leave the executive board by mutual agreement with immediate effect on July 7th, 2020 due to different strategic visions. Mr. Roedder will leave the BRAIN AG at the end of the calendar year.

Dr Georg Kellinghusen, Chairman of the Supervisory Board, states: "We like to thank Ludger Roedder for his contribution and commitment to the development of the BRAIN AG since 2018 and wish him the most success for his next ventures. We feel very comfortable with the future setup of a two person’s board consisting of Adriaan Moelker, CEO, and Lukas Linnig, CFO. Currently we are not planning a succession for Ludger Roedder".

About BRAIN

B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN DE0005203947 / WKN 520394) is one of Europe’s leading technology companies in the field of industrial biotechnology, the core discipline of the bioeconomy. As such, BRAIN identifies previously untapped efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by means of “Nature’s Toolbox” are successfully applied in the chemicals, cosmetics and food industries. BRAIN's business model is based on two pillars. The BioScience segment mainly comprises research and development business with industrial partners, and the company’s own research and development. The BioIndustrial segment consists mainly of business with industrially scalable products. As part of a growth-oriented industrialization strategy, BRAIN AG has been listed on the Prime Standard of the Frankfurt Stock Exchange since February 2016 as the first company in the bioeconomy. Further information is available at www.brain-biotech.com.

Disclaimer

This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN AG and are based on information currently available to the management. Forward-looking statements are not guarantees of future performance and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. There are numerous factors which could influence the future performance by and future developments at BRAIN AG and the BRAIN group of companies. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, and other factors. BRAIN AG does not undertake any obligation to update or revise any forward-looking statements.

Share this page